CN104335046B - 方法 - Google Patents

方法 Download PDF

Info

Publication number
CN104335046B
CN104335046B CN201380023276.5A CN201380023276A CN104335046B CN 104335046 B CN104335046 B CN 104335046B CN 201380023276 A CN201380023276 A CN 201380023276A CN 104335046 B CN104335046 B CN 104335046B
Authority
CN
China
Prior art keywords
akt3
emt
expression
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380023276.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104335046A (zh
Inventor
J.洛伦斯
C.蒂隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Publication of CN104335046A publication Critical patent/CN104335046A/zh
Application granted granted Critical
Publication of CN104335046B publication Critical patent/CN104335046B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
CN201380023276.5A 2012-05-02 2013-05-02 方法 Expired - Fee Related CN104335046B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641512P 2012-05-02 2012-05-02
GB201207722A GB201207722D0 (en) 2012-05-02 2012-05-02 Method
US61/641,512 2012-05-02
GB1207722.8 2012-05-02
PCT/IB2013/053488 WO2013164788A2 (en) 2012-05-02 2013-05-02 Method

Publications (2)

Publication Number Publication Date
CN104335046A CN104335046A (zh) 2015-02-04
CN104335046B true CN104335046B (zh) 2019-10-11

Family

ID=46330714

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023276.5A Expired - Fee Related CN104335046B (zh) 2012-05-02 2013-05-02 方法

Country Status (13)

Country Link
US (2) US10317405B2 (enExample)
EP (1) EP2845004A2 (enExample)
JP (2) JP2015525060A (enExample)
KR (1) KR102179389B1 (enExample)
CN (1) CN104335046B (enExample)
AU (1) AU2013255456B2 (enExample)
BR (1) BR112014027219A2 (enExample)
CA (1) CA2871352A1 (enExample)
EA (1) EA201401201A1 (enExample)
GB (1) GB201207722D0 (enExample)
IN (1) IN2014MN02114A (enExample)
SG (1) SG11201407032WA (enExample)
WO (1) WO2013164788A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523776A (ja) * 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
GB201420239D0 (en) * 2014-11-14 2014-12-31 Bergenbio As Biomarker
GB201512133D0 (en) * 2015-07-10 2015-08-19 Bergenbio As Biomarkers
KR101941054B1 (ko) * 2016-07-20 2019-01-23 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102080384B1 (ko) * 2018-02-28 2020-02-21 주식회사 마크로젠 암줄기세포 특이적 바이오마커
SG11202104963WA (en) * 2018-11-12 2021-06-29 Agency Science Tech & Res Methods for manipulating cell state transitions in cancer
KR20230019109A (ko) * 2020-05-08 2023-02-07 조지아뮨 엘엘씨 Akt3 조절제 및 이의 사용 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
CN1809536A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
CN102421919A (zh) * 2009-03-13 2012-04-18 卑尔根技术交易股份公司 采用AxI作为上皮-间质转化的生物标志物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809194B1 (en) 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
US20040121413A1 (en) 2002-12-20 2004-06-24 Aebersold Rudolf H. Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
EP2173352B1 (en) * 2007-07-12 2016-09-07 University of South Florida Inhibitors of akt/pkb with anti-tumor activity
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
EP2235179B1 (en) 2007-12-24 2017-11-15 BerGenBio ASA Methods for creating and identifying functional rna interference elements
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2010083465A1 (en) 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2010091354A2 (en) 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
WO2010115119A2 (en) * 2009-04-02 2010-10-07 Tufts Medical Center, Inc. Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents
WO2011050351A2 (en) 2009-10-23 2011-04-28 The Translational Genomics Research Institute Methods and kits used in identifying glioblastoma
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
SG10201505769PA (en) 2010-07-27 2015-09-29 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
WO2012032143A1 (en) * 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
WO2012061510A2 (en) * 2010-11-03 2012-05-10 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
CN1809536A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
CN102421919A (zh) * 2009-03-13 2012-04-18 卑尔根技术交易股份公司 采用AxI作为上皮-间质转化的生物标志物的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Axl is essential for VEGF-A-dependent activation of PI3K/Akt;Guo-Xiang Ruan 等;《The EMBO Journal》;20120210;第31卷(第7期);第1692-1703页 *

Also Published As

Publication number Publication date
AU2013255456A1 (en) 2014-11-13
WO2013164788A2 (en) 2013-11-07
KR102179389B1 (ko) 2020-11-18
KR20150016518A (ko) 2015-02-12
IN2014MN02114A (enExample) 2015-09-04
EP2845004A2 (en) 2015-03-11
CA2871352A1 (en) 2013-11-07
US20200072839A1 (en) 2020-03-05
GB201207722D0 (en) 2012-06-13
WO2013164788A3 (en) 2014-01-23
AU2013255456B2 (en) 2018-07-26
CN104335046A (zh) 2015-02-04
US10317405B2 (en) 2019-06-11
BR112014027219A2 (pt) 2017-06-27
JP2015525060A (ja) 2015-09-03
SG11201407032WA (en) 2014-11-27
JP2017136077A (ja) 2017-08-10
JP6738755B2 (ja) 2020-08-12
US20150119475A1 (en) 2015-04-30
EA201401201A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
CN104335046B (zh) 方法
CN102421919B (zh) 采用Axl作为上皮‑间质转化的生物标志物的方法
JP6599334B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
US20180320185A1 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
US20120039805A1 (en) Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
US20120190565A1 (en) Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
US20130059903A1 (en) Compositions and Methods for Characterizing Breast Cancer
ES2873377T3 (es) Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón
WO2017064159A1 (en) Trpv2 as a biomarker and as a therapeutic target for melanoma
US11035008B2 (en) Biomarkers for cancer
US20170314077A1 (en) Slfn11 as biomarker for aml
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
US20170258871A1 (en) Combined use of a trka inhibitor and an epha2 inhibitor for using in the treatment of solid cancers, and method for the prognosis of survival of a patient who has a solid cancer
EP4361136A1 (en) Compound for the treatment of glioblastoma
KR101916564B1 (ko) 신경교종의 혈관신생억제제에 대한 반응성 예측 판단용 바이오마커
CN117136309A (zh) 用于恶性周围神经鞘瘤的鉴别诊断的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191011